{"id":78505,"date":"2026-09-03T16:55:50","date_gmt":"2026-09-03T08:55:50","guid":{"rendered":"https:\/\/flcube.com\/?p=78505"},"modified":"2026-09-03T16:55:50","modified_gmt":"2026-09-03T08:55:50","slug":"everest-medicines-wins-nmpa-approval-for-etripamil-nasal-spray-cardamyst-in-psvt-bringing-er-free-arrhythmia-care-to-greater-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78505","title":{"rendered":"Everest Medicines Wins NMPA Approval for Etripamil Nasal Spray Cardamyst in PSVT, Bringing ER\u2011Free Arrhythmia Care to Greater China"},"content":{"rendered":"\n

Everest Medicines<\/strong> (HKG: 1985<\/a>) announced today that its etripamil<\/strong> nasal spray has received marketing approval from China’s National Medical Products Administration (NMPA)<\/strong> for the acute treatment of paroxysmal supraventricular tachycardia (PSVT)<\/strong> in adults, with the goal of converting episodes back to sinus rhythm. The therapy will be commercialized under the brand name Cardamyst<\/strong>, marking the first self\u2011administered, rapid\u2011onset treatment option of its kind for PSVT patients in Greater China and a potential shift in how episodic cardiac events are managed \u2014 from the emergency room to the outpatient setting.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/td>National Medical Products Administration (NMPA)<\/strong>, China<\/td><\/tr>
Approval Type<\/td>Marketing authorization<\/td><\/tr>
Product<\/td>Etripamil<\/strong> nasal spray, branded Cardamyst<\/strong><\/td><\/tr>
Indication<\/td>Acute treatment of paroxysmal supraventricular tachycardia (PSVT)<\/strong> in adults to convert to sinus rhythm<\/td><\/tr>
Approval Date<\/td>Sept 3, 2026<\/td><\/tr>
Next Steps<\/td>Commercial launch and outpatient rollout across Greater China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n